On March 21, 2017, the FDA made a safety announcement about a link between textured breast implants and a very rare form of cancer: anaplastic large-cell lymphoma. In the announcement, the FDA called the cancer “breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).
Dr. Saltz puts the safety of his patients first and foremost, so he has never used textured implants in his augmentation procedures.
What the FDA said
The FDA only issued the “association” for textured implants. Here is some additional information.
This is what the FDA said in its announcement, “All of the information to date suggests that women with breast implants have a very low but increased risk of developing anaplastic large-cell lymphoma compared to women who do not have breast implants.” It specifically cited implants with “textured surfaces” in their announcement.
What is ALCL?
ALCL is an uncommon cancer that can develop in any part of the body, most commonly the lymph nodes and skin. Research suggests that BIA-ALCL is usually found near the breast implant within the surrounding scar tissue, not in the breast itself. The lifetime risk for developing BIA-ALCL from a textured implant is estimated to be from one in 4,000 to one in 30,000. At this point, the type of implant (silicone or saline) doesn’t seem make a difference. It is the implant texture.
How is BIA-ALCL treated?
This is still a very rare risk. Plus, when BIA-ALCL is caught early it is usually curable. Treatment involved surgical removal of the implants and the scar tissue capsule, as the lymphoma appears almost always to be only in the scar tissue capsule.
Dr. Saltz’s policy
Dr. Saltz has never used textured implants for his augmentation procedures. This link with textured implants and BIA-ALCL only reinforces his position on this.
Do you have questions about your implants? Call Dr. Saltz at (801) 274-9500 or (435) 655-6612.